Immunic Advances Vidofludimus Calcium Therapy for Multiple Sclerosis with Promising Q3 Results

Immunic Inc has reported strong Q3 highlights, focusing on its oral MS treatment vidofludimus calcium. The company presented important new data from several clinical studies at the ECTRIMS conference, including results from the CALLIPER study and EMPhASIS phase 2 open-label extension trial. Vidofludimus calcium showed a statistically significant effect on confirmed disability improvement and a numerical benefit in slowing disability worsening in primary progressive MS patients. The drug's durability and favorable safety and tolerability profile were also highlighted.